Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma

Cancer Letters
Terence Kin Wah LeeIrene Oi Lin Ng

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy worldwide and has poor prognosis. Existing treatment modalities, including surgery, chemotherapy, and radiofrequency ablation, which target tumor bulk, have demonstrated limited therapeutic efficacy. In the past 10years, accumulating evidence has supported the existence of cancer stem cells (CSCs) or tumor initiating cells (T-ICs) within tumors including HCC. Identification of liver T-ICs and the signaling pathways that they are involved in may shed light on novel therapeutic strategies against this deadly disease. In this review, we will discuss recent progresses made in the research of liver T-ICs with regard to identification, functional characterization, regulation and therapeutic implications.

References

Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Josep M Llovet, Jordi Bruix
Feb 11, 2004·Proceedings of the National Academy of Sciences of the United States of America·Bangyan StilesHong Wu
Apr 24, 2004·Science·Soraya YektaDavid P Bartel
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Siu Tim CheungSheung Tat Fan
Jun 27, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Tetsuhiro ChibaHideki Taniguchi
Jun 16, 2007·Gastroenterology·Stephanie MaXin-Yuan Guan
Feb 5, 2008·Cancer Cell·Zhen Fan YangSheung Tat Fan
Feb 16, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Zhen Fan YangSheung Tat Fan
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 9, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jenny C HoSheung Tat Fan
Oct 18, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chuan YinWei-Fen Xie
Jul 9, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Junfang JiXin Wei Wang
Sep 3, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Eleonora PatsenkerDetlef Schuppan
Mar 3, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hanning YouC Bart Rountree
Mar 11, 2010·Liver International : Official Journal of the International Association for the Study of the Liver·Feng YuJinjun Li
Jul 22, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Tetsuhiro ChibaAtsushi Iwama
Jul 29, 2010·Seminars in Liver Disease·Olivier Rosmorduc, Chantal Housset
Aug 5, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xiao Qi WangSheung Tat Fan
Aug 11, 2010·The Journal of Clinical Investigation·Naotsugu HaraguchiMasaki Mori
Oct 28, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Terence Kin Wah LeeIrene Oi Lin Ng
Apr 27, 2011·Clinical and Experimental Medicine·Fei TianAlbrecht Bergner
Apr 27, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hye Jung BaekLopa Mishra
Jul 8, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Wen SunHong-Yang Wang
Sep 21, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chao WangHong-Yang Wang
Oct 14, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kwan Ho TangKwok Wah Chan
Nov 5, 2011·International Journal of Cancer. Journal International Du Cancer·Xiao Qi WangSheung Tat Fan
Dec 24, 2011·PloS One·Phyllis Fung Yi CheungSiu Tim Cheung

❮ Previous
Next ❯

Citations

May 4, 2013·Stem Cells and Development·George S WilsonLiang Qiao
Jan 5, 2013·Toxicological Sciences : an Official Journal of the Society of Toxicology·Takeki UeharaIvan Rusyn
Feb 21, 2014·Seminars in Immunology·Koji Taniguchi, Michael Karin
Jul 19, 2014·Nature Reviews. Drug Discovery·John G MoffatDavid Bailey
Sep 27, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Vidya GanapathyCharles M Roth
Oct 16, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yabo OuyangDexi Chen
Apr 28, 2016·Stem Cells International·Sabrina BimonteFrancesco Izzo
Oct 15, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Haili HuangMingyi Li
Jan 1, 2014·Cancer Letters·Jin Ding, Hongyang Wang
Feb 6, 2019·Journal of Clinical Medicine·Cristian TuratoPatrizia Pontisso
Aug 8, 2013·Nature Medicine·Andrew S LeeJoseph C Wu
Oct 27, 2018·Journal of Cellular Physiology·Khalil HajiasgharzadehBehzad Baradaran
Mar 8, 2017·Expert Opinion on Drug Delivery·Lucia ScarabelBarbara Dapas
Nov 1, 2017·World Journal of Gastroenterology : WJG·Teresita Nj Flores-TéllezCarolina Piña-Vázquez
Nov 16, 2017·International Journal of Oncology·Youping WeiLiming Zhang
Jun 30, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Cristian ScheauMonica Neagu
Feb 6, 2019·Therapeutic Advances in Gastroenterology·Na Li, Ying Zhu
Jun 25, 2019·Frontiers in Pharmacology·Aurélien HaustrateV'yacheslav Lehen'kyi
Nov 7, 2019·World Journal of Stem Cells·Clara SteichenAnne Dubart-Kupperschmitt
Jan 1, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·George Denis Alexandru PopescuConstantin Caruntu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.